君实生物：预计2025年年度净利润为-8.73亿元左右

Group 1 - The core viewpoint of the article is that Junshi Bioscience expects a reduction in net loss for the year 2025, projecting a net loss of approximately 873 million yuan, which is a decrease of about 408 million yuan compared to the previous year, representing a year-on-year reduction of approximately 31.85% [1] - The main reason for the change in performance is attributed to an increase in operating revenue, primarily driven by the growth in sales revenue of commercialized drugs compared to the same period last year [1] Group 2 - The article highlights a surge in nuclear power construction, indicating that equipment manufacturers are extremely busy, with orders scheduled until 2028, and employees working in three shifts with production lines operating 24 hours a day [1]